Advancing the Diagnosis and Treatment of Ovarian Cancer
insights from industryDr. Marcos Quintela VasquezResearch and Development Innovation OfficerRBGO Research Group
In this interview, News-Medical talks to Dr. Marcos Quintela Vasquez about the work he is conducting regarding the diagnosis and treatment of ovarian cancer in partnership with CEAT and Porvair Sciences.
Please tell us about CEAT, your project aims and how the group of partners was assembled?
The Cluster for Epigenomic and Antibody Drug Conjugate (ADC) Therapeutics (CEAT) is a Swansea University-led partnership between key multi-national players Glaxo Smith Kline (GSK), Cytiva and Bruker, together with UK-based partners Porvair Sciences Ltd, Axis Bio, and BiVictriX. The CEAT project, jointly funded by the Welsh European Funding Office and collaborating partners, is designed to enable partners to deliver advances in epigenetic and ADC-based ovarian cancer therapeutics.
Journal of Lower Genital Tract Disease publishes a clinical trial endorsing PAPILOCARE as a proven treatment that prevents and treats lesions caused by HPV
of patients affected by high-risk HPV
The Paloma Clinical trial also certifies a clearance of HPV in 63% of patients with high-risk HPV treated with PAPILOCARE compared with 40% in the control group.
MADRID, Spain, April 7, 2021 /PRNewswire/
The
Journal of Lower Genital Tract Disease (JLGTD), the official journal of the American Society for Colposcopy and Cervical Pathology (ASCCP),
have published the final results of the Paloma Clinical Trial, which demonstrated the efficacy of PAPILOCARE in preventing and treating lesions caused by HPV. Its main conclusions include the
Research highlights improved outcomes in ovarian surgery
Implementation of a multidisciplinary surgical team (MDT), using a meticulous approach for ensuring a patient is in optimum clinical condition prior to surgery, results in significantly improved rates of complete resection of ovarian cancer, according to new Irish research.
An MDT comprises gynaecologic oncologists and colorectal, hepatobiliary and upper gastrointestinal surgeons.
A study published in the January 2021 edition of the
Annals of Surgical Oncology Journal (
ASOJ) examined two cohorts of patients. Cohort A was a retrospectively collated group of patients that presented with ovarian cancer between 2006 and 2015 and who were generally offered neoadjuvant (delivered before the main treatment, to help reduce the size of a tumour) chemotherapy.
Singula Bio provides new hope for cancer with diverse, individualised therapies pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Department of Belarus national cancer center certified as European Ovarian Cancer Surgery Center
An archive photo
MINSK, 13 January (BelTA) – The European Society of Gynaecological Oncology (ESGO) has certified the Department of Gynecology Oncology of N.N. Alexandrov National Cancer Center of Belarus as the Advanced Ovarian Cancer Surgery Center. The certificate was issued for five years, BelTA learned from the press service of the Healthcare Ministry.
The European Society of Gynaecological Oncology advances treatment, care and research of gynecological cancer. ESGO certification can be issued only to the centers with a wealth of experience in surgical treatment of advanced ovarian cancer. ESGO certificate confirms the high professionalism of all specialists involved in the treatment of this disease.